. "Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
Provost, P.J., B.S.Wolanski, W.J.Miller, O.L.Ittensohn, W.J. McAleer, and M.R.Hilleman. 1975. Physical, chemical and morphologic dimensions of human hepatitis A virus strain CR326. Proc. Soc. Exp. Biol. Med. 148(2):532–539.
Provost, P.J., F.S.Banker, P.A.Giesa, W.J.McAleer, E.B.Buynak, and M.R.Hilleman. 1982. Progress toward a live, attenuated human hepatitis A vaccine. Proc. Soc. Exp. Biol. Med. 170(1):8–14.
Provost, P.J., P.A.Conti, P.A.Giesa, F.S.Banker, E.B.Buynak, W.J. McAleer, and M.R.Hilleman. 1983. Studies in chimpanzees of live, attenuated hepatitis A vaccine candidates. Proc. Soc. Exp. Biol. Med. 172(3):357–363.
Purcell, R.H., S.M.Feinstone, J.R.Ticehurst, R.M.Daemer, and B.M. Baroudy. 1984. Hepatitis A virus. Pp. 9–22 in Viral Hepatitis and Liver Disease, G.N.Vyas, J.L.Dienstag, and J.H.Hoofnagle, eds. Orlando, Fla.: Grune and Stratton.
World Health Organization. 1981. World Health Organization Annual Statistical Reports, Vol. 1 and 2. Geneva: World Health Organization.
